----------------------------------------------------------------------------------------------------------------
The ILLUMINATE-204 trial is enrolling two distinct patient populations,
both patients who are naïve to ipilimumab therapy (N=40; Primary
Efficacy Endpoint Population) and patients who have prior ipilimumab
experience (N=Up to 20; Secondary Efficacy Endpoint Population). Of the
initial 21 patients available for efficacy evaluations 6 of 17 patients
from the Primary Efficacy Endpoint Population and 2 of 4 patients from
the Secondary Efficacy Endpoint Population achieved RECIST v.1.1
responses, further demonstrating a signal that tilsotolimod has the
potential to help overcome prior ipilimumab resistance.